文献速递外周动脉疾病

血管钙化是复杂股腘动脉病变置入Zilver PTX药物涂层支架后支架内再狭窄的危险因素

Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
PubMed 文献 · J Endovasc Ther · 2019-07-01

这项回顾性多中心研究纳入220例症状性患者共230条肢体,评估股腘动脉病变置入Zilver PTX药物涂层支架后血管钙化对支架内再狭窄的影响。多因素分析显示双侧血管壁钙化(PACSS 3-4)是支架内再狭窄的独立危险因素(校正HR 1.718,95%CI 1.035-2.851,p=0.036),病变长度亦相关,而西洛他唑给药具有保护作用(校正HR 0.476,95%CI 0.259-0.876,p=0.017)。

要点

  • 双侧血管壁钙化(PACSS 3-4)是Zilver PTX支架置入后支架内再狭窄的独立危险因素。
  • 病变长度增加与支架内再狭窄风险升高独立相关。
  • 西洛他唑给药与支架内再狭窄风险降低独立相关。

核心结论

  • 双侧血管壁钙化是复杂股腘动脉病变置入Zilver PTX药物涂层支架后支架内再狭窄的独立危险因素,病变长度亦相关,西洛他唑给药具有保护作用。

研究设计与样本

  • 回顾性多中心研究纳入220例连续症状性患者(平均年龄73.1±8.3岁,175例男性)共230条肢体,股腘动脉病变接受Zilver PTX药物涂层支架治疗并于术后行双功超声监测。

主要发现

  • 1年、2年、5年主要通畅率分别为75.9%、63.6%、45.0%,免于临床驱动的靶病变血运重建率分别为84.7%、73.7%、54.2%。
  • 随访期间4条肢体接受大截肢。
  • 多因素分析显示血管钙化(校正HR 1.718,95%CI 1.035-2.851,p=0.036)、病变长度(校正HR 1.041,95%CI 1.013-1.070,p=0.003)与支架内再狭窄显著相关,西洛他唑给药(校正HR 0.476,95%CI 0.259-0.876,p=0.017)与支架内再狭窄风险降低显著相关。

关键数值与推荐

  • 钙化按外周动脉钙化评分系统(PACSS)评估,病变分为PACSS 0-2(无或单侧壁钙化)与PACSS 3-4(双侧壁钙化)。
  • 148处(64.3%)病变存在钙化;104处(45.2%)为完全闭塞,68处(29.6%)为支架内再狭窄,20条(8.7%)血管无流出道。

临床怎么用

  • 对于复杂股腘动脉病变拟置入Zilver PTX药物涂层支架者,应评估血管壁钙化程度(PACSS分级)以预判支架内再狭窄风险。
  • 双侧壁钙化(PACSS 3-4)及长病变患者术后需加强双功超声监测。
  • 西洛他唑给药可能与支架内再狭窄风险降低相关,可作为术后药物治疗的参考。

局限性

  • 本研究为回顾性设计,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To evaluate the effect of vessel calcification on in-stent restenosis (ISR) after drug-coated stent (DCS) placement in the femoropopliteal segment. Materials and Methods: A retrospective multicenter study was undertaken involving 220 consecutive symptomatic patients (mean age 73.1±8.3 years; 175 men) with femoropopliteal lesions in 230 limbs treated with the Zilver PTX DCS and having duplex surveillance after the endovascular procedures. Mean lesion length was 16.4±9.8 cm (range 2-40); there were 104 (45.2%) total occlusions and 68 (29.6%) in-stent restenoses (ISR). Twenty (8.7%) vessels had no runoff. The majority of lesions (148, 64.3%) were calcified according to the peripheral arterial calcium scoring system (PACSS). Primary patency was evaluated by duplex. Lesions were classified as either PACSS 0-2 (none or unilateral wall calcification) or PACSS 3 and 4 (bilateral wall calcification). Multivariate analysis was performed to identify variables associated with ISR; the results are given as the hazard ratio (HR) and 95% confidence interval (CI). Results: The 1-, 2-, and 5-year primary patency and freedom from clinically-driven target lesion revascularization estimates were 75.9%, 63.6%, and 45.0%, and 84.7%, 73.7%, and 54.2%, respectively. Major amputations were performed on 4 limbs during follow-up. In multivariate analysis, vessel calcification (adjusted HR 1.718, 95% CI 1.035 to 2.851, p=0.036) was significantly correlated with the occurrence of ISR, along with lesion length (adjusted HR 1.041, 95% CI 1.013 to 1.070, p=0.003), and cilostazol administration (adjusted HR 0.476, 95% CI 0.259 to 0.876, p=0.017). Conclusion: This study suggested that bilateral vessel wall calcification was an independent risk factor for ISR in complex femoropopliteal lesions after Zilver PTX DCS placement, along with lesion length; cilostazol administration had a protective effect.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Ichihashi S, Shibata T, Fujimura N, et al. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement. J Endovasc Ther. 2019. PMID: 31257994. doi:10.1177/1526602819860124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。